WoW - Single- vs Two-staged Excisions of Thin Melanoma

The overall aim of this national, multicenter, prospective, randomized, and controlled study is to enhance the management of patients with thin melanoma (≤1 mm Breslow thickness). The investigators hypothesize that wide local excisions (WLEs) following complete excision of thin melanoma do not affect the risk of recurrence, defined as the occurrence of local, regional, distant disease, or melanoma-specific death during a 5- to 10-year follow-up period.

Trial Details

NCT ID
NCT06363591
Phase
NA
Sponsor
Vastra Gotaland Region
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Surgery
  • No Surgery
Locations (sample)
  • Gothenburg, Sweden|57.70716,11.96679

Key Eligibility Criteria

  • Patients need to fulfill all criteria listed below:
  • Has recently been diagnosed with a primary invasive cutaneous melanoma of Breslow thickness ≤1.0 mm (pT1) as determined by a diagnostic excision wi…
  • Is located on a body location in which a WLE with a 10-mm clinical margin is feasible and would have been planned according to current standard of …
  • Had histopathologically verified free margins of at least 1.5 mm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →